Oncotarget

Research Papers:

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab

Jitka Mlcochova _, Petra Faltejskova-Vychytilova, Manuela Ferracin, Barbara Zagatti, Lenka Radova, Marek Svoboda, Radim Nemecek, Stanislav John, Igor Kiss, Rostislav Vyzula, Massimo Negrini and Ondrej Slaby

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:38695-38704. https://doi.org/10.18632/oncotarget.5735

Metrics: PDF 1271 views  |   HTML 1153 views  |   ?  


Abstract

Jitka Mlcochova1, Petra Faltejskova-Vychytilova1,2, Manuela Ferracin3, Barbara Zagatti3, Lenka Radova1, Marek Svoboda2, Radim Nemecek2, Stanislav John4, Igor Kiss2, Rostislav Vyzula2, Massimo Negrini3, Ondrej Slaby1,2

1Central European Institute of Technology, Masaryk University, Brno, Czech Republic

2Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Masaryk University, Faculty of Medicine, Brno, Czech Republic

3Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

4Department of Oncology and Radiotherapy, Faculty Hospital Hradec Kralove, Hradec Kralove, Czech Republic

Correspondence to:

Ondrej Slaby, e-mail: on.slaby@gmail.com

Massimo Negrini, e-mail: ngm@unife.it

Keywords: microRNA, metastatic colorectal cancer, EGFR, cetuximab, panitumumab

Received: May 17, 2015     Accepted: October 08, 2015     Published: October 20, 2015

ABSTRACT

The aim of our study was to investigate whether microRNAs (miRNAs) could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in patients with RAS wild-type (wt-RAS) metastatic colorectal cancer (mCRC). Historical cohort of 93 patients with mCRC (2006–2009) was included and further divided into exploratory and validation cohorts. MiRNAs expression profiling was performed on the exploratory cohort of 41 wt-KRAS mCRC patients treated with cetuximab to identify miRNAs associated with time to progression (TTP). The validation was performed on two independent cohorts: 28 patients of wt-RAS mCRC treated with cetuximab and 24 patients of wt-RAS mCRC treated with panitumumab. We identified 9 miRNAs with significantly different expression between responders and non-responders to cetuximab therapy (P ≤ 0.01). These 9 miRNAs were further evaluated in two independent cohorts of patients and miR-31-3p (P < 0.001) and miR-31-5p (P < 0.001) were successfully confirmed as strongly associated with TTP in wt-RAS mCRC patients treated with cetuximab but not panitumumab. When evaluated on the complete cohort of cetuximab patients (N = 69), miR-31-3p (HR, 5.10; 95% CI, 2.52–10.32; P < 0.001) and miR-31-5p (HR, 4.80; 95% CI, 2.50–9.24; P < 0.001) were correlated with TTP on the comparable level of significance. There was no difference in miR-31-5p/3p expression levels in RAS mutated and wild-type tumor samples. MiR-31-5p/3p are promising predictive biomarkers of cetuximab response in wt-RAS mCRC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5735